597 related articles for article (PubMed ID: 17495126)
1. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
[TBL] [Abstract][Full Text] [Related]
2. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.
Stephan D; Winkler M; Kühner P; Russ U; Quast U
Diabetologia; 2006 Sep; 49(9):2039-48. PubMed ID: 16865362
[TBL] [Abstract][Full Text] [Related]
3. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
[TBL] [Abstract][Full Text] [Related]
4. Glibenclamide binding to sulphonylurea receptor subtypes: dependence on adenine nucleotides.
Hambrock A; Löffler-Walz C; Quast U
Br J Pharmacol; 2002 Aug; 136(7):995-1004. PubMed ID: 12145099
[TBL] [Abstract][Full Text] [Related]
5. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.
Hansen AM; Hansen JB; Carr RD; Ashcroft FM; Wahl P
Br J Pharmacol; 2005 Feb; 144(4):551-7. PubMed ID: 15678092
[TBL] [Abstract][Full Text] [Related]
6. Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel.
Ashfield R; Gribble FM; Ashcroft SJ; Ashcroft FM
Diabetes; 1999 Jun; 48(6):1341-7. PubMed ID: 10342826
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a mutant sulfonylurea receptor SUR2B with high affinity for sulfonylureas and openers: differences in the coupling to Kir6.x subtypes.
Hambrock A; Löffler-Walz C; Russ U; Lange U; Quast U
Mol Pharmacol; 2001 Jul; 60(1):190-9. PubMed ID: 11408614
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
[TBL] [Abstract][Full Text] [Related]
9. Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain.
Chen M; Dong Y; Simard JM
J Neurosci; 2003 Sep; 23(24):8568-77. PubMed ID: 13679426
[TBL] [Abstract][Full Text] [Related]
10. [Structures and mechanisms for non SU insulin secretagogues].
Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
[No Abstract] [Full Text] [Related]
11. The mutation Y1206S increases the affinity of the sulphonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2.
Stephan D; Stauss E; Lange U; Felsch H; Löffler-Walz C; Hambrock A; Russ U; Quast U
Br J Pharmacol; 2005 Apr; 144(8):1078-88. PubMed ID: 15711591
[TBL] [Abstract][Full Text] [Related]
12. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels.
Chachin M; Yamada M; Fujita A; Matsuoka T; Matsushita K; Kurachi Y
J Pharmacol Exp Ther; 2003 Mar; 304(3):1025-32. PubMed ID: 12604678
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes.
Meyer M; Chudziak F; Schwanstecher C; Schwanstecher M; Panten U
Br J Pharmacol; 1999 Sep; 128(1):27-34. PubMed ID: 10498831
[TBL] [Abstract][Full Text] [Related]
14. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
Hansen AM; Christensen IT; Hansen JB; Carr RD; Ashcroft FM; Wahl P
Diabetes; 2002 Sep; 51(9):2789-95. PubMed ID: 12196472
[TBL] [Abstract][Full Text] [Related]
15. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors.
Schwanstecher M; Sieverding C; Dörschner H; Gross I; Aguilar-Bryan L; Schwanstecher C; Bryan J
EMBO J; 1998 Oct; 17(19):5529-35. PubMed ID: 9755153
[TBL] [Abstract][Full Text] [Related]
16. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure.
Dörschner H; Brekardin E; Uhde I; Schwanstecher C; Schwanstecher M
Mol Pharmacol; 1999 Jun; 55(6):1060-6. PubMed ID: 10347249
[TBL] [Abstract][Full Text] [Related]
17. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
Gribble FM; Tucker SJ; Seino S; Ashcroft FM
Diabetes; 1998 Sep; 47(9):1412-8. PubMed ID: 9726229
[TBL] [Abstract][Full Text] [Related]
18. The Kir6.2-F333I mutation differentially modulates KATP channels composed of SUR1 or SUR2 subunits.
Tammaro P; Ashcroft F
J Physiol; 2007 Jun; 581(Pt 3):1259-69. PubMed ID: 17395632
[TBL] [Abstract][Full Text] [Related]
19. Regulation of cloned ATP-sensitive K channels by adenine nucleotides and sulfonylureas: interactions between SUR1 and positively charged domains on Kir6.2.
John SA; Weiss JN; Ribalet B
J Gen Physiol; 2001 Oct; 118(4):391-405. PubMed ID: 11585851
[TBL] [Abstract][Full Text] [Related]
20. Sulfonylurea receptors type 1 and 2A randomly assemble to form heteromeric KATP channels of mixed subunit composition.
Chan KW; Wheeler A; Csanády L
J Gen Physiol; 2008 Jan; 131(1):43-58. PubMed ID: 18079561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]